During this panel discussion we discussed how hybrid LBA/LC–MS assays are used, reflecting on the use of the technique in analysis of large molecules. We also discussed methodological practices, covering internal standards, purification methods and detection platforms.
Our panelists addressed the benefits of using hybrid LBA/LC–MS compared with LBA and LC–MS individually. With a wealth of experience, our experts provided relevant insight on key issues surrounding hybrid LBA/LC–MS technology and offered advice on best practice.
What will you learn?
- Development of hybrid LBA/LC–MS assays
- Internal standards and methodological practices to apply
- Acceptance criteria to apply for drug analysis
- Advantages of utilizing hybrid techniques versus LBA and LC–MS individually
Who may this interest?
- CROs, pharmaceutical and biotechnology companies focused on LC–MS/MS quantitative bioanalysis of large molecules
- Small molecule (LC–MS) bioanalytical scientists with an interest in large molecule quantitation
- Bioanalysts with a background in LBAs interested in LC–MS
Rand Jenkins is Scientific Director for the Chromatographic Sciences Department (CSD) of PPD Laboratories bioanalytical lab in Richmond (VA, USA) and Middleton (WI, USA). Since obtaining a BS in chemistry from the University of Nevada Reno in 1972, Rand has been involved for over 40 years in the development and applications of GC– and LC–MS technologies in the environmental and pharmaceutical fields. He joined PPD in 1994 and currently provides scientific guidance to the R&D teams in bioanalytical methods development and validation. Rand’s major focus in recent years has been to establish and promote bioanalysis of peptides and proteins using LC–MS technology.
Carsten Krantz studied Biotechnology at the Mannheim University of Applied Science. After this, he moved to Basel to do a PhD in Glycobiology at the Friedrich-Miescher Institute. In 2010 he joined Novartis as a lab head to set up a mass spectrometry laboratory for Biologics. Within Novartis he introduced techniques like hybrid LC–MS/MS in a regulated DMPK environment and routinely conducts pre-clinical and clinical pharmacokinetic and pharmacodynamics studies for large molecules by LC–MS/MS.
Suma Ramagiri received a BSc in Biochemistry and an MSc in Organic Chemistry in India. She did her PhD in Analytical Chemistry and post-doctoral research at the University of Tennessee Health Sciences, Memphis (TN, USA). Suma obtained Business Management from Ryerson University (Toronto, Canada). Suma brings more than 15 years of experience in the analytical instrumentation field while working at Dr Reddy’s Laboratories Hyderabad, India, and GTx. Inc. and ED Labs in Memphis (TN, USA). She worked in many drug discovery and development projects for antibacterial, anti-inflammatory and anticancer drugs, DMPK studies and GLP bioanalysis. In her current role as a Global Application Manager, Pharmaceutical & CRO business at SCIEX, Suma leads innovative analytical and bioanalytical workflows in both traditional small molecule and also various biologic compound classes such as peptides, proteins, oligonucleotides, monoclonal antibodies and antibody–drug conjugates, a growing segment within Pharma and Biopharma. She drove worldwide efforts in application development and analytical product development to enhance bioanalytical quantitation, drug metabolism, biomarker quantitation, metabolomics and impurity analysis. Suma has over 15 publications in scientific journals and has presented at conferences and tradeshows worldwide. In her current role as Senior Manager, Suma is responsible for SCIEX global pharma/biopharma quant and metabolism revenue and product/solution strategy.
Dr Wang received his PhD in analytical chemistry at Michigan State University in 1994. Following postdoctoral training at the National Institutes of Health, he joined GSK in 1996 and then Bristol-Myers Squibb in 1997. Dr Wang has 20 years of experience in bioanalysis in pharmaceutical industry. In recent years, Dr Wang has been leading a group of scientists in developing hybrid ligand binding and LC–MS assays for ADC bioanalysis in an LBA and LC–MS integrated approach. Currently, Dr Wang serves as the coordinator of Regulated Bioanalysis Interest Group at ASMS and a sub-team lead of AAPS ADC bioanalysis committee.
Megan is a ligand binding assay scientist with 17 years of industry experience. She joined a large CRO immediately after graduating from George Mason University. She has extensive experience on the bench, as a Bioanalytical Principal Investigator and as a Manager overseeing LBA method development, validation, and sample analysis. Her expertise includes working with novel biologics including multivalent antibodies, antibody fragments, and antibody–drug conjugates. Her interaction with these molecules also involves coordinating with LC–MS teams across protocols that use hybrid LBA/LC–MS methods in addition to LBAs. Megan joined PPD in 2012 and is now a Manager in their Immunochemistry Department.